Alan Leichtman, MD
Dr. Alan Leichtman is a Professor of Medicine in the Division of Nephrology of the University of Michigan, and has served as the Primary Physician for the University of Michigan’s Kidney and Pancreas Transplantation Programs since 1989 and as the Medical Director of the University of Michigan’s Kidney and Pancreas Transplantation Programs from 1989 through 2005. He directs the University’s Kidney Paired Donation system and is co-director of its Transplant Nephrology Fellowship program.
He is President-Elect of Gift of Life Michigan, the State of Michigan’s Organ Procurement Organization. Dr. Leichtman is also a Board Member of the Gift of Life Foundation, and a Past-President and Board Member of the Great Lakes Transplantation Society
Nationally, he is a Member of the Board of Directors of the U.S. Organ Donation and Transplantation Alliance, the Board of Trustees of the American Kidney Fund, the National Kidney Foundation’s End-The-Wait Task Force, the American Society of Nephrology’s Transplant Advisory Committee, the American Society of Transplantation Public Policy Committee, and the Alliance for Paired Donation’s Scientific Operations Committee. He previously served as a Transplant Investigator for the Scientific Registry of Transplant Recipients (SRTR) and is currently the Associate Director of the data coordinating center for the RELIVE Study, a National Institute of Health sponsored, multicenter epidemiological investigation of living lung and living kidney donor outcomes. He is a previous Chair of the Organ Procurement and Transplantation Network’s (OPTN/UNOS) Kidney and Pancreas Transplantation Committee, and of the American Society of Transplantation’s Patient Care and Education Committee, and a previous member of the OPTN/UNOS Membership and Professional Standards Committee, and the American Society of Transplantation Scientific Studies Committee.
Dr. Leichtman’s research interests include the clinical outcomes of kidney and pancreas transplantation, kidney paired donation, and the effects of allocation rules and other public policies on access to and outcomes of solid organ transplantation.